Oncocyte (NSDQ:OCX) announced yesterday that it entered into a development and co-marketing agreement with Thermo Fisher Scientific (NYSE:TMO).
The development and co-marketing agreement covers two distributed in vitro diagnostic (IVD) assays on Thermo Fisher’s Ion Torrent Genexus system and grants Oncocyte the rights to develop future companion diagnostics on the Genexus system.
Under the collaboration terms, Oncocyte will clinically validate Thermo Fisher’s existing Oncomine Comprehensive Assay Plus on the Genexus system to accelerate it toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic, according to a news release.
The 500-gene assay could initially provide physicians with information about tumors in accordance with established clinical evidence, Oncocyte said.
Oncocyte will also develop its 27-gene expression DetermaIO test as a distributed kit on Thermo Fisher’s Genexus platform…